Volume 29, Number 9—September 2023
Research
Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020–2021
Katherine Newell
, Marc Fischer, Stephanie Massey, Laurie Orell, Jonathan Steinberg, Megan Tompkins, Louisa Castrodale, and Joseph McLaughlin
, Marc Fischer, Stephanie Massey, Laurie Orell, Jonathan Steinberg, Megan Tompkins, Louisa Castrodale, and Joseph McLaughlin
Table 3
Streptococcus pneumoniae serotype by vaccine type among patients who had IPD temporally associated with SARS-CoV-2 infection or IPD alone, Alaska, USA, 2020–2021*
| S. pneumoniae serotype by vaccine type | IPD patients with SARS-CoV-2 infection, no. (%), n = 55 | IPD patients without SARS-CoV-2 infection, no. (%), n = 216 |
|---|---|---|
| PCV13 + 6C† | 30 (55) | 137 (63) |
| PPSV23, non-PCV13‡ | 18 (33) | 50 (23) |
| Nonvaccine type | 6 (11) | 9 (4) |
| Unknown | 1 (2) | 20 (9) |
*IPD, invasive pneumococcal disease; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine. †Serotypes contained in PCV13 (i.e., 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) plus serotype 6C. ‡Serotypes contained in PPSV23 but not in PCV13 (i.e., 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, 33F).
Page created: July 20, 2023
Page updated: August 20, 2023
Page reviewed: August 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential